biOasis Technologies Ord Shs V.BTI.H

Alternate Symbol(s): BIOAF

Healthcare Biotechnology

Bioasis Technologies Inc. is a Canada-based biopharmaceutical company focused on research and development of technologies and products intended for the treatment of patients with nervous system, including central nervous system, diseases and disorders. The Company is engaged in the development of its xB 3 platform, which is a peptide-based technology, for the transport of therapeutic agents, in particular biological products, across the blood-brain barrier (BBB). It is focused on both orphan drug indications, including brain cancers, and rare genetic neurodegenerative diseases and neuroinflammatory conditions. The Company is also focused on its Epidermal Growth Factor (EGF) platform for treating rare and orphan neurodegenerative and neuroinflammatory disorders. EGF is a protein that stimulates cell growth and differentiation, notably for myelin producing cells. Its development programs include xB3-001: Brain Metastases, xB3-002: Glioblastoma and xB3-007: Neurodegenerative Disease.

TSXV:BTI.H - Post by User

biOasis Technologies Ord Shs

Bullboard Posts

Post by BearDownAZon Sep 28, 2015 2:24pm

175 Views

Post# 24141940

A couple upcoming Gabathuler presentations

I found a couple of upcoming talks that Reinhard Gabathuler is presenting at. One is tomorrow at the 2nd Zing Barriers of The CNS Conference 2015 in a 45 minute time slot in the following session:

Session 8 - Brain Delivery Technologies: Antibody Engineering, Protein Vectors and Brain Shuttles - Current Technologies in Brain Targeting

Session Chairs: Danica Stanimirovic & Reinhard Gabathuler

15:00 - 15:45 Danica Stanimirovic Blood-Brain Barrier Shuttles and Trojans: Development of Brain Targeting Antibody Therapeutics

15:45 - 16:30 Reinhard Gabathuler Development of New Protein Vectors for the Delivery of Large Therapeutic Compounds to Treat CNS Disorders

16:30 - 16:50 Wandong Zhang Development of FC5hFc-Doxorubicin Conjugate for Drug Delivery Across the Blood-Brain Barrier.

The other is a Partnerships in Drug Delivery conference in Boston next week Octoober 5-6.

Sure has been quiet on the communication front from the company lately......

Bullboard Posts

Paramount Resources signs $3.32 billion asset sale